Last reviewed · How we verify
Newly matched donor-derived FL-33 CAR T therapy
Newly matched donor-derived FL-33 CAR T therapy is a Small molecule drug developed by Beijing GoBroad Hospital. It is currently in Phase 1 development.
At a glance
| Generic name | Newly matched donor-derived FL-33 CAR T therapy |
|---|---|
| Sponsor | Beijing GoBroad Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Newly matched donor-derived FL-33 CAR T therapy CI brief — competitive landscape report
- Newly matched donor-derived FL-33 CAR T therapy updates RSS · CI watch RSS
- Beijing GoBroad Hospital portfolio CI
Frequently asked questions about Newly matched donor-derived FL-33 CAR T therapy
What is Newly matched donor-derived FL-33 CAR T therapy?
Newly matched donor-derived FL-33 CAR T therapy is a Small molecule drug developed by Beijing GoBroad Hospital.
Who makes Newly matched donor-derived FL-33 CAR T therapy?
Newly matched donor-derived FL-33 CAR T therapy is developed by Beijing GoBroad Hospital (see full Beijing GoBroad Hospital pipeline at /company/beijing-gobroad-hospital).
What development phase is Newly matched donor-derived FL-33 CAR T therapy in?
Newly matched donor-derived FL-33 CAR T therapy is in Phase 1.